Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

47.20 -0.05 (-0.12%)

Streaming Delayed Price Updated: 1:07 PM EDT, Aug 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

99 100 Next >

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

February 19, 2026

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Via The Motley Fool

Topics Intellectual Property

Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗

February 19, 2026

Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.

Via The Motley Fool

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗

February 12, 2026

Via Stocktwits

HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? ↗

February 11, 2026

Via Stocktwits

Hims & Hers HUGE Acquisition News! ↗

February 19, 2026

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.

Via The Motley Fool

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗

February 19, 2026

Ozempic's rival is generating blockbuster revenue and gaining market share.

Via The Motley Fool

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Topics Earnings Economy

NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗

February 17, 2026

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Via Stocktwits

Topics Lawsuit

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Viking should have plenty of news to share with investors this year.

Via The Motley Fool

Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗

February 16, 2026

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Via The Motley Fool

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

Via The Motley Fool

Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗

February 13, 2026

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.

Via Stocktwits

Topics Lawsuit

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗

February 13, 2026

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Via The Motley Fool

Topics Intellectual Property

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗

February 12, 2026

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Via Stocktwits

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗

February 12, 2026

Both companies are betting on interest in weight loss pills.

Via The Motley Fool

Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs ↗

February 12, 2026

Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year.

Via Benzinga

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗

February 11, 2026

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

Via Stocktwits

Topics Intellectual Property

The Greenland Gambit: Inside the Transatlantic Tariff Shock and the Future of Arctic Sovereignty

February 11, 2026

As of February 11, 2026, the global economy is navigating the aftershocks of a geopolitical standoff that nearly dismantled the post-war trade order. The "Greenland Tariff Escalation," a high-stakes...

Via MarketMinute

Topics Bonds Economy Government

Disney Has Its Next CEO ↗

February 11, 2026

Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March.

Via The Motley Fool

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗

February 11, 2026

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Via The Motley Fool

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Via The Motley Fool

Topics Artificial Intelligence

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

This stock has been known to soar after good news.

Via The Motley Fool

Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗

February 10, 2026

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.

Via The Motley Fool

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

February 10, 2026

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Via Stocktwits

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

The stock has climbed in the triple digits over the past three years.

Via The Motley Fool

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit ↗

February 09, 2026

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny.

Via The Motley Fool

Topics Artificial Intelligence Lawsuit Stocks

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗

February 09, 2026

Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.

Via The Motley Fool

Topics Intellectual Property Lawsuit

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

February 09, 2026

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.